The global pediatric diabetes therapeutic market is set to reach USD 1,633.8 million in 2024. Projections indicate that the sector is anticipated to elevate to USD 2,612.4 million by 2034. The industry stood at USD 1,540.2 million in 2023 and is anticipated to exhibit a Y-o-Y growth of 6.1% in 2024. Demand for pediatric diabetes therapeutics is slated to surge at a 4.8% CAGR.
Global healthcare expenditure is rising due to increased access, economic growth, and government initiatives to improve healthcare infrastructure. This has led to more resources being allocated to diabetes management and treatment, fueling growth.
Governments worldwide are implementing awareness campaigns, early screening programs, reimbursement policies, and incentives for developing innovative treatments. Increased awareness has led to early diagnosis, better management practices, and surging demand for effective treatments.
Developments in medical technology, such as continuous glucose monitoring systems and insulin pumps, are improving diabetes management and patient outcomes. Technological developments are further set to fuel the market by offering more precise and convenient treatment options.
Insulin is vital for pediatric diabetes management, with several formulations available to mimic natural secretion. Continuous glucose monitoring (CGM) systems provide real-time blood sugar readings. Demand is set to rise as these enable timely insulin dose adjustments and prevent hypoglycemic or hyperglycemic episodes for patients.
The focus on personalized medicine in pediatric diabetes care is increasing due to developments in genetic testing and biomarker analysis. This allows healthcare providers to customize treatment based on individual patient characteristics, potentially optimizing treatment outcomes and minimizing adverse effects.
Digital health technologies, such as smartphone apps, wearable devices, and telemedicine, are being integrated into pediatric diabetes management. These are further enabling remote monitoring and education for patients. New technologies enhance patient engagement, empowerment, and treatment adherence, leading to improved clinical outcomes and a better patient experience.
The industry is gaining traction in the healthcare sector, propelled by developments in insulin therapy, glucose monitoring, personalized medicine, and digital health technologies. The global rise in pediatric diabetes, largely due to unhealthy diets, necessitates innovative solutions to enhance outcomes.
| Attributes | Description |
|---|---|
| Estimated Global Pediatric Diabetes Therapeutic Market Size (2024E) | USD 1,633.8 million |
| Projected Global Pediatric Diabetes Therapeutic Market Value (2034F) | USD 2,612.4 million |
| Value-based CAGR (2024 to 2034) | 4.8% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Innovations in Drug Delivery Format
Increasing prevalence of diabetes in pediatrics due to genetic inheritance has led to a strong demand for effective drug treatments. The demand for pharmaceutical preparations that can be administered to pediatric patients without discomfort is on the rise.
For instance, according to a study published by the National Library of Medicine, the most common problem among babies and children for rejection and spitting out medicine was the bad taste of drugs. Moreover, the other problem related to drug administration tools reported was the fear of injections among children.
To address such issues, several manufacturers are focusing on the development of drugs that can be administered through a route that is both convenient and safe for the pediatric population. The introduction of easily administered pharmaceutical products for diabetic pediatrics is set to create lucrative growth opportunities for key manufacturers.
For instance, in June 2023, Amphastar Pharmaceuticals, Inc. acquired BAQSIMI from Eli Lilly and Company. BAQSIMI, a nasal spray designed for treating severe hypoglycemia in diabetic patients aged four and above, demonstrates the industry's dedication to pediatric diabetes care.
Collaborations between Leading Organizations to Gain Traction
Emerging nations' focus on improving healthcare affordability through infrastructure development is projected to boost demand for pediatric diabetes therapeutic products. Pharmaceutical manufacturers are collaborating with non-profit organizations to raise awareness about pediatric diabetes in remote developing regions, focusing on establishing a presence.
Limited Awareness Hindering Growth
Diabetes severity among pediatric populations is exacerbated by factors such as genetic history complexities, lack of financial capability, and limited access to healthcare facilities. Limited awareness about diabetes symptoms and a scarcity of clinical specialists are set to impede growth. Economic difficulties, inadequate income sources, and insufficient health insurance coverage are further projected to limit growth in the industry.
The global pediatric diabetes therapeutic industry recorded a historical CAGR of 4% from 2019 to 2023. Pediatric diabetes cases are primarily attributed to favorable family history, insulin resistance, maternal gestational diabetes, and autoimmune diseases.
For instance, according to an article published by Forbes Media LLC in February 2024, depending on the geographic location, age, and gender, around 22 out of every 100,000 children in the United States are diagnosed with type 1 diabetes every year. Insulin delivery devices like pens and pumps have transformed pediatric diabetes care, offering convenience, precision, and flexibility compared to traditional syringes. These developments empowered young patients and caregivers to manage diabetes more effectively.
By 2034, the market is set to rise at a substantial growth rate. This growth is attributed to the increasing number of clinical studies on existing diabetic drugs for the measurement of safety in pediatrics. Growing focus of pharmaceutical manufacturers on receiving approvals for drugs in different geographic locations is another significant factor fueling growth.
Pharmaceutical manufacturers are implementing strategic initiatives in collaboration with competitors to research and develop new molecular entities. Increasing focus on raising awareness about the rising prevalence of diabetes among the pediatric population is projected to continue.
For instance, in June 2023, Boehringer Ingelheim and Eli Lilly and Company received approval for Jardiance from the United States FDA. These tablets are indicated for lowering blood sugar levels in children aged ten years and older with type 2 diabetes.
Principal Consultant
The section below covers the forecast for the pediatric diabetic therapeutic sector in terms of countries. Information on key countries in several parts of the globe, including North America, Asia Pacific, and Europe, is provided. The section also shows the industry size in a graphical presentation in leading countries.
The United States is anticipated to remain at the forefront in North America, with a CAGR of 5.4% through 2034. In East Asia, China is projected to witness a CAGR of 5.3% by 2034, leaving behind India at 4.5% in South Asia and Pacific.
| Countries | CAGR 2024 to 2034 |
|---|---|
| United States | 5.4% |
| China | 5.3% |
| Germany | 4.8% |
| United Kingdom | 4.4% |
| India | 4.5% |
The United States is set to surge at a CAGR of 5.4% by 2034. This dominance is projected to persist, offering a stable growth trajectory throughout the forecast period. A burgeoning pediatric population grappling with inherited complexities of ancestors is the key factor propelling growth.
Healthcare insurance coverage provided by the government further anticipates growth in the United States. Moreover, initiatives taken by pediatric hospitals in collaboration with universities to escalate services to the pediatric population are set to fuel pediatric diabetes therapeutic sales.
For instance, in February 2023, St. Louis Children’s Hospital collaborated with the Washington University School of Medicine to announce the availability of the first mobile pediatric diabetes unit in the United States. This collaboration focuses on assisting students in managing diabetes and is a part of the Healthy Kids Express umbrella program.
Increasing incidence of type 2 diabetes among children due to rising rates of childhood obesity is set to contribute to growth in Germany. The country is at the forefront of innovation in pediatric diabetes care, focusing on personalized medicine. Leading companies are offering genetic testing, biomarker analysis, and precision medicine to tailor treatments based on individual patient characteristics.
Digital health technologies, such as smartphone apps, wearable devices, and telemedicine platforms, are also transforming diabetes management in Germany. These technologies enhance access to care, patient engagement, and adherence to treatment plans.
Clinical research and innovation are fueling pediatric diabetes therapeutics. These are evaluating novel insulin formulations, drug delivery devices, and adjunctive therapies to enhance glycemic control.
Increasing consumption of processed meat and sugar-sweetened beverages among pediatric populations is anticipated to bolster growth in China. By 2034, the country is projected to rise at a CAGR of 5.3%.
Rising burden of diabetes among the pediatric population due to the high number of individuals with inherited genetic complexities is a key factor contributing to growth. Pediatric diabetes care in China relies on patient education and support programs, providing resources, counseling, and peer support to empower young patients and families.
The section contains information about the leading segments in the industry. This data is significant for leading companies to evaluate several segments and influence growth. In terms of diabetes, the type 1 segment is set to account for 56.2% share by 2024. By therapy, the insulin therapy segment is projected to hold a 57.2% share in 2024.
| Segment | Type 1 (Diabetes) |
|---|---|
| Value Share (2024) | 56.2% |
The type 1 diabetes segment is set to lead the diabetes category with a 56.2% share in 2024 and is projected to rise at a substantial CAGR throughout the forecast period. Rising prevalence of type 1 diabetes among pediatric populations is mainly attributed to family history, genetic inheritance, and environmental factors. For instance, according to an article published by Merck & Co., Inc., type 1 diabetes is the most common condition among children and accounts for around two-thirds of the new cases in children of all ethnic groups.
| Segment | Insulin Therapy (Therapy) |
|---|---|
| Value Share (2024) | 57.2% |
The insulin therapy segment is projected to dominate the category by holding around 57.2% share in 2024. The segment is estimated to continue experiencing steady growth by 2034. Clinicians are increasingly recommending insulin as the first-line treatment for pediatric diabetes. This is because the hormone helps maintain blood sugar levels and prevent complications, contributing to growth.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
In the dynamic landscape of pediatric diabetes therapeutics, key companies, and manufacturers are emphasizing the development and launch of new products in the market. Leading manufacturers are also focusing on strategic acquisitions for the growth of product portfolios.
Key manufacturers are focusing on research and development of novel therapeutic options to reach a wide audience and enhance presence. Companies are directed toward partnerships, collaborations, and alliances to enhance research and commercialization expertise. Manufacturers are also partnering with local pharmaceutical companies and start-ups to develop effective entry strategies for emerging sectors.
Industry Updates
In terms of diabetes, the category is divided into type 1 and type 2.
The industry is segregated into drug therapy and insulin therapy. Drug therapy is further divided into biguanide and sodium-glucose co-transporter 2 (SGLT2) inhibitors. Insulin therapy is sub-segmented into rapid-acting insulin, short-acting insulin, intermediate-acting insulin, and long-acting insulin.
The industry is segregated into oral administration, nasal administration, and parenteral administration. The parental administration segment is further trifurcated into subcutaneous, intramuscular, and intravenous.
A few of the important distribution channels include institutional sales, retail sales, and online pharmacy. Further, the institutional sales segment is branched into hospitals, specialty clinics, and others. Along with that, the retail sales segment is divided into retail pharmacies and drug stores.
Key countries of North America, Latin America, East Asia, South Asia and Pacific, Western Europe, Eastern Europe, and the Middle East and Africa are covered.
The industry is set to witness a CAGR of 4.8% by 2034.
The industry witnessed a CAGR of 4% from 2019 to 2023.
In 2034, the sector is anticipated to reach USD 2,612.4 million.
Germany is estimated to lead by showcasing a 4.8% CAGR through 2034.
Boehringer Ingelheim International GmbH, Eli Lilly and Company, and Sanofi.
The sector is projected to reach USD 1,633.8 million in 2024.
1. Executive Summary 2. Industry Introduction, including Taxonomy and Market Definition 3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments 4. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, including Historical Analysis and Future Projections 5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034 5.1. By Diabetes 5.2. By Therapy 5.3. By Route of Administration 5.4. By Distribution Channel 5.5. By Region 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Diabetes 6.1. Type 1 6.2. Type 2 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Therapy 7.1. Drug Therapy 7.1.1. Biguanide 7.1.2. Sodium-glucose co-transporter 2 (SGLT2) inhibitors 7.2. Insulin Therapy 7.2.1. Rapid-acting Insulin 7.2.2. Short-acting Insulin 7.2.3. Intermediate-acting Insulin 7.2.4. Long-acting Insulin 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Route of Administration 8.1. Oral Administration 8.2. Nasal Administration 8.3. Parenteral Administration 8.3.1. Subcutaneous 8.3.2. Intramuscular 8.3.3. Intravenous 9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Distribution Channel 9.1. Institutional Sales 9.1.1. Hospitals 9.1.2. Specialty Clinics 9.1.3. Others 9.2. Retail Sales 9.2.1. Retail Pharmacies 9.2.2. Drug Stores 9.3. Online Pharmacy 10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Region 10.1. North America 10.2. Latin America 10.3. Western Europe 10.4. Eastern Europe 10.5. East Asia 10.6. South Asia and Pacific 10.7. Middle East and Africa 11. North America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 12. Latin America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 13. Western Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 14. Eastern Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 15. East Asia Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 16. South Asia & Pacific Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 17. Middle East and Africa Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 18. Sales Forecast 2024 to 2034 by Diabetes, Therapy, and Route of Administration for 30 Countries 19. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard 20. Company Profile 20.1. Boehringer Ingelheim International GmbH. 20.2. Eli Lilly and Company 20.3. Sanofi 20.4. Vertex Pharmaceuticals Incorporated 20.5. Novo Nordisk A/S 20.6. AstraZeneca 20.7. MannKind Corporation 20.8. Xeris Pharmaceuticals 20.9. Amphastar Pharmaceuticals, Inc.
Explore Healthcare Insights
View Reports
Pediatric Diabetes Therapeutic Market
